HMI-115
also HMI
BAY-1158061, also known as HMI-115, is a monoclonal antibody against the prolactin receptor (PRLR) which is under development for the treatment of alopecia and endometriosis. It is taken by long-lasting subcutaneous injection. BAY-1158061 has been reported to promote hair growth in balding stump-tailed macaques. The drug was first described in the scientific literature by 2018. It is under development by Bayer and Hope Medicine. As of June 2025, BAY-1158061 is in phase 2 clinical trials for alopecia and endometriosis. Multiple phase 2 trials have been completed, including trials for both alopecia and endometriosis. The chemical structure of BAY-1158061 does not yet appear to have been disclosed.
Read “BAY-1158061” on Wikipedia · text from Wikipedia, CC BY-SA 4.0
Information, not medical advice. Talk to a licensed doctor or pharmacist before starting or changing a treatment.
Research 10
- The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithms
- Topical application of the Wnt/<i>β</i>-catenin activator methyl vanillate increases hair count and hair mass index in women with androgenetic alopecia
- Cross-section Trichometry: A Clinical Tool for Assessing the Progression and Treatment Response of Alopecia
- Evaluation of Cohen's Cross-Section Trichometer for Measuring Hair Quantity
- Patient-reported outcome assessment and objective evaluation of chemotherapy-induced alopecia
- Hair mass index obtained by cross-section trichometry: an objective and clinically useful parameter to quantify hair in chemotherapy-induced alopecia
- Exhaustive analysis of scalp hair regression: subjective and objective perception from initial hair loss to severe miniaturisation and drug-induced regrowth
- HairMeasure: A Cost-Effective Device for Measuring Hair Mass Index
- A dietary supplement improves age-related dermatological changes. Observational, anecdotal, spontaneous study.
- A Study on the Effectiveness and Safety of Herbal Extract Combination Compared to 3% Minoxidil Solution for the Treatment of Androgenetic Alopecia: A Randomized, Double-blind, Controlled Trial
Community 10
- Does anyone know when HMI-115 Phase 1 Australian study is supposed to end?
- Dutasteride SAVES your hair follicles: MAJOR BS on people who say it destroyed their hair permanently.
- What's going on with hmi115? The Phase 2 was concluded Nov2024 but no news
- Are there ever going to be any oral DHT blocking treatments in the future?
- Prolactin the Cause of Hair Loss? ABS-201 the Cure?
- What an amazing time to be alive
- HopeMed (Hmi115) is pissed at Absci (Abs-201)
- Hope Medicine's HMI-115 could be out in 2027 per Company Founder
- Is hmi 115 the cure? Or is it 🧢 just like cosmeRNA, brezula, pyrilutamide, and other 📞 ies
- Would you continue to use Finasteride and Minoxidil once HMI 115 becomes available?